Deck 23: Inflammatory Tumoroncology Imaging and Therapy

Question 1

The radiopharmaceutical used to gather additional diagnostic information on a patient with pulmonary lesions found on CT is

A) (^99mTc-depreotide.)
B) (¹²³ I-MIBG.)
C) (¹¹¹In-capromab pendetide.)
D) (¹¹¹In-pentetreotide.)

Answer 1

(^99mTc-depreotide.)

Question 2

Patient preparation for an ¹¹¹In-capromab pendetide imaging procedure should include

A) the administration of a diuretic 24 hours prior to injection.
B) adequate hydration prior to imaging.
C) an enema during the 24 hours prior to injection.
D) an enema on the morning of the imaging.

Answer 2

an enema on the morning of the imaging.

Question 3

A ⁶⁷Ga image at 48 hours after injection displays bowel activity; the technologist should

A) be concerned that the wrong radiopharmaceutical was administered.
B) change the collimator to reduce the scatter activity from the bowel.
C) continue imaging because this is normal.
D) check to see if a radiographic study using contrast was performed.

Answer 3

continue imaging because this is normal.

Question 4

The radionuclide used for imaging in the diagnostic assessment of prostate cancer is

A) (^99mTc-sestamibi)
B) (^99mTc-arcitumomab)
C) (¹¹¹In-capromab pendetide)
D) (¹¹¹In-pentetreotide)

Question 5

A patient arrives in a nuclear medicine department for therapy for non-Hodgkin lymphoma (NHL). The radioimmunotherapy used is

A) (⁸⁹Sr-chloride.)
B) (⁹⁰Y-ibritumomab tiuxetan.)
C) (¹⁵³Sm-lexidronam.)
D) (³²P-phosphate.)

Question 6

The radionuclide used in the diagnostic evaluation of recurrent or metastatic colorectal cancer is

A) (^99mTc-sestamibi.)
B) (^99mTc-arcitumomab.)
C) (¹¹¹In-capromab pendetide.)
D) (¹¹¹In-pentetreotide.)

Question 7

A patient with bilateral breast cancer is being prepared for scintimammography. The technologist will administer the ^99mTc-MIBI via

A) IV injection in the left arm.
B) IV injection in the contralateral arm.
C) IV injection in the foot.
D) IV injection in either arm.

Question 8

In imaging with ⁶⁷Ga-citrate, target-to-background ratio increases over time because of gallium concentration in tissue

A) remaining the same while blood clearance progresses.
B) decreasing while blood clearance progresses.
C) remaining the same while blood clearance decreases.
D) decreasing while blood clearance decreases.

Question 9

How many radionuclides are currently approved by the FDA for the treatment of bone pain?

A) None
B) Two
C) Four
D) Seven

Question 10

A technologist is performing a parathyroid study using MIBI. After the flow study, the first phase (thyroid phase) of imaging should begin within

A) 5 to 10 minutes.
B) 15 to 20 minutes.
C) 60 to 90 minutes.
D) 120 minutes.

Question 11

Rituximab (Rituxan) is administered as a(n)

A) bolus IV injection.
B) infusion over 2 to 6 hours.
C) IV injection over 10 minutes.
D) catheter instillation.

Question 12

Among the safety instructions a technologist will provide to a patient following ⁹⁰Y-ibritumomab tiuxetan administration is to

A) avoid contact with children for 1 to 2 weeks.
B) have home health care for first 3 days following release.
C) use disposable eating utensils.
D) use effective contraceptive methods for 1 year.

Question 13

Following the injection of ⁶⁷Ga-citrate, imaging can begin

A) immediately.
B) at 1 hour.
C) at 3 hours.
D) at 6 hours.

Question 14

Patient preparation for a ^99mTc-depreotide study includes

A) hydration prior to and following injection.
B) administration of a thyroid blocking agent.
C) IV administration of a glucose solution.
D) a laxative at 24 hours prior to imaging.

Question 15

All of the following are disadvantages of ¹¹¹In-WBCs as compared to ⁶⁷Ga, EXCEPT

A) lower specificity.
B) requires a large blood volume.
C) lower counting statistics.
D) not suitable for delayed imaging beyond 24 hours.

Question 16

A technologist is positioning a patient for a ⁶⁷Ga-citrate imaging study and notices that a LEAP collimator is on the camera. The recommended action for the technologist to take is to

A) continue positioning the patient; the correct collimator is in place.
B) change the collimator to a GAP collimator.
C) change the collimator to a medium-energy collimator.
D) change the collimator to a high-energy collimator.

Question 17

The radionuclide used to visualize primary neuroendocrine tumors is

A) (^99mTc-sestamibi.)
B) (^99mTc-arcitumomab.)
C) (¹¹¹In-capromab pendetide.)
D) (¹¹¹In-pentetreotide.)

Question 18

A patient's indication for a nuclear medicine study is primary pheochromocytoma. The radiopharmaceutical that the technologist prepares for administration is

A) (^99mTc-depreotide.)
B) (¹²³ I-MIBG.)
C) (¹¹¹In-capromab pendetide.)
D) (¹¹¹In-pentetreotide.)

Question 19

Meta-iodobenzylguanidine (MIBG) acts as an analog to

A) glucagon.
B) neuroepinephrine.
C) calcium.
D) somatostatin.

Question 20

For optimal targeting and minimal blood pool activity, ¹¹¹In-capromab pendetide imaging should begin at

A) 6 to 24 hours after injection.
B) 36 to 48 hours after injection.
C) 60 to 90 hours after injection.
D) 96 to 120 hours after injection.

Question 21

Once ^99mTc-sulfur colloid is administered as a pretreatment for abdominal malignant effusion therapy, the patient is instructed to

A) refrain from any exercise for the following 4 hours.
B) drink fluids and void frequently.
C) roll from side to side for 60 to 90 minutes.
D) return the following day for administration of the therapy dose.

Question 22

Which organ is the most common site of metastasis for cancers of the abdominal organs?

A) Liver
B) Lungs
C) Bone
D) Brain

Question 23

Which is NOT a radionuclide used for treatment of bone pain?

A) (³²P-sodium phosphate)
B) (¹²³I-tositumomab)
C) (¹⁵³Sm-lexidronam)
D) (²²³Ra dichloride)

Question 24

A patient has polycythemia vera; the technologist will prepare the patient for the administration of

A) (³²P-sodium phosphate.)
B) (³²P-chromic phosphate.)
C) (⁸⁹Sr-chloride.)
D) (¹²³I-tositumomab.)

Question 25

A patient who is to undergo radionuclide therapy for an abdominal malignant effusion is prepared for

A) an IV injection of ³²P-sodium chloride.
B) an IV injection of ³²P-chromic phosphate.
C) an abdominal instillation of ³²P-sodium chloride.
D) an abdominal instillation of ³²P-chromic phosphate.

Question 26

In selective internal radiation therapy (SIRT), ⁹⁰Y microspheres are administered in incremental

A) infusions into the renal vein.
B) infusions into the renal artery.
C) infusions into the hepatic vein.
D) infusions into the hepatic artery.